Cargando…

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder

PURPOSE: We performed a meta-analysis to evaluate the efficacy and safety of mirabegron add-on therapy to solifenacin for patients with overactive bladder (OAB). METHODS: We conducted a systematic literature review to identify all randomized, double-blind, controlled trials (RCTs) of this combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yankai, Liu, Ruihua, Liu, Chu, Cui, Yuanshan, Gao, Zhenli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Continence Society 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636960/ https://www.ncbi.nlm.nih.gov/pubmed/28954464 http://dx.doi.org/10.5213/inj.1734934.467

Ejemplares similares

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)
por: Drake, Marcus J., et al.
Publicado: (2017)

A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
por: Kumar, Shailendra, et al.
Publicado: (2023)

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study
por: Kim, Seong Cheol, et al.
Publicado: (2021)

Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study
por: Tang, Qing-lai, et al.
Publicado: (2022)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
por: Makhani, Asad, et al.
Publicado: (2020)

Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study
por: Kakizaki, Hidehiro, et al.
Publicado: (2020)

Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial
por: Hsiao, Sheng-Mou, et al.
Publicado: (2022)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
por: Sartori, Luisa Gracio Ferreira, et al.
Publicado: (2023)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis
por: Su, Shunye, et al.
Publicado: (2020)

Solifenacin significantly improves all symptoms of overactive bladder syndrome
por: CHAPPLE, C R, et al.
Publicado: (2006)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
por: Yamanishi, Tomonori, et al.
Publicado: (2020)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
por: Shaw, Christina, et al.
Publicado: (2023)

Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study
por: van Rey, Farida, et al.
Publicado: (2011)

Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
por: Wang, Hui, et al.
Publicado: (2017)

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis
por: Kennelly, Michael, et al.
Publicado: (2022)

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus‐1 associated myelopathy
por: Matsuo, Tomohiro, et al.
Publicado: (2018)

Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study
por: Choo, M-S, et al.
Publicado: (2008)

Long‐term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study
por: Mueller, Elizabeth R., et al.
Publicado: (2019)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Cardiovascular safety of mirabegron add‐on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study
por: Katoh, Takao, et al.
Publicado: (2020)

The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
por: Masumori, Naoya, et al.
Publicado: (2010)

Efficacy and safety of mirabegron in the treatment of overactive bladder syndrome after radical prostatectomy: a prospective randomized controlled study
por: Li, Wang, et al.
Publicado: (2023)

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
por: Kennelly, Michael J., et al.
Publicado: (2021)

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database
por: Chapple, Christopher R., et al.
Publicado: (2016)

Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis
por: Majdinasab, Nastaran, et al.
Publicado: (2023)

A phase II dose-ranging study of mirabegron in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2013)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
por: Allison, Sara J., et al.
Publicado: (2018)

Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)
por: Nakagomi, Hiroshi, et al.
Publicado: (2022)

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
por: Ito, Hidenori, et al.
Publicado: (2022)

Long‐term safety and efficacy of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study)
por: Yamaguchi, Osamu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5peldfa8g334kj3buph9r3mj2e